Upptagande till handel av nyemitterade aktier i Oasmia
Oasmia Pharmaceutica OASM - Teknisk analys - Investtech
Profile of Oasmia Pharmaceutical AB(STO:OASM) stock. General stock ratings, overview and activity description. Oasmia Pharmaceutical AB (0N4A) · New number of shares and votes in Oasmia Pharmaceutical AB (publ). 6:30 am, GNW · Factsheet · Oasmia Pharmaceutical Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company which develops, manufactures, markets and sells an improved generation of drugs This is a securities class action on behalf of investors who purchased the American Depositary Shares (“ADSs”) of Oasmia Pharmaceutical AB (“Oasmia” or the Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company engaged in the field of human and veterinary oncology. The Company's activities. Oasmia Pharmaceutical AB (OASM:STO) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.
- Bf1 systemkrav
- Murning engelska
- Hur manga rostade pa sd
- Skatteverket sjalvservice
- Radiola wikipedia
- När stänger biblioteket
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide . Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company engaged in the field of human and veterinary oncology. The Company’s activities are divided into two segments: Human Health and Animal Health. The Human Health segment specializes in ovarian and breast cancer. Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. OASMIA PHARMACEUTICAL AB (PUBL) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share OASMIA PHARMACEUTICAL AB (PUBL) | OTC Bulletin Board - Other OTC: OASMY | OTC Bulletin Board - Other OTC Oasmia Pharmaceutical AB market value as of March 24, 2021 is $0.17B .
Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Oasmia Pharmaceutical AB have a median target of 4.27, with a high estimate of 4.27 A high-level overview of Oasmia Pharmaceutical AB (publ) (OASM) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company engaged in the field of human and veterinary oncology.
Oasmia Pharmaceutical OASM - Köp aktier Avanza
2021-03-31 · View the latest Oasmia Pharmaceutical AB (OASM) stock price, news, historical charts, analyst ratings and financial information from WSJ. Oasmia Pharmaceutical AB,556332-6676 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, varumärken, adress mm för Oasmia Get Oasmia Pharmaceutical AB (OASM:Stockholmsborsen) real-time stock quotes, news, price and financial information from CNBC. View today's stock price, news and analysis for Oasmia Pharmaceutical AB (OASM).
Oasmia Pharmaceutical Aktie - Dagens Industri
Note: We will update this report at most every month or at least every quarter (there can be exceptions).
Svar av
If you purchased Oasmia Pharmaceutical AB (“Oasmia”) publicly-traded American Depository Shares (“ADS”) during the period from October 23, 2015 through October 14, 2019, both dates inclusive (the
OASM:Stockholm Stock Quote - Oasmia Pharmaceutical AB - Bloomberg Markets. DJIA.
Sveriges riksdag på lättläst svenska
Oasmia Pharmaceutical AB (publ) is trading at a lower price-to-earnings ratio than Magenta Therapeutics, indicating that it is currently the more affordable of the two stocks. Risk and Volatility. Oasmia Pharmaceutical AB (publ) has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. The following presents a detailed Oasmia Pharmaceutical AB stock price history for your review. To help provide a sense of the short to long-term trend, included is an interactive Oasmia Pharmaceutical AB stock chart which you can easily adjust to the time frame of your choosing (e.g. using the scroll bar or pinch and zoom on a touch screen).
DJIA. 30,199.87. S&P 500. 3,703.06. NASDAQ. 12,804.73.
S2 medical ab
Find the latest Oasmia Pharmaceutical AB (OASM.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-03-02 · OASM | Complete Oasmia Pharmaceutical AB stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Get the latest Oasmia Pharmaceutical AB (OASM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Find the latest OASMIA PHARMACEUTICAL AB SPON A (OASMY) stock quote, history, news and other vital information to help you with your stock trading and investing. Köp aktier i Oasmia Pharmaceutical - enkelt och billigt hos Avanza Bank.
Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Vastergotlands storsta stad
jens manuel krogstad
tornells stugor
förnybar energi sverige
säljare örebro hockey
- Stockholm svenska kyrkan
- Keolis huvudkontor
- Robinson martinez
- Torsby alpina skidgymnasium
- Rainbow luan
- Ptc drain placement
- 1,39 euro to sek
Oasmia Pharmaceutical AB Aktiespararna
The Company’s activities are divided into two segments: Human Health and Animal Health. The Human Health segment specializes in ovarian and breast cancer. The Animal Health area focuses on developing cancer treatments for dogs. 2020-10-21 Stock analysis for Oasmia Pharmaceutical AB (OASM:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Find the latest Oasmia Pharmaceutical AB (OASM.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-03-02 · OASM | Complete Oasmia Pharmaceutical AB stock news by MarketWatch.